Coles Anthony N.'s Insider Trades & SAST Disclosures
Coles Anthony N.'s most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,958 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern Coles Anthony N..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals,...
|
N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
|
Regeneron Pharmaceuticals,...
|
N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 1,559 (0%) | 0% | 0 | Common Stock | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 25,000 | 2,177,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 41.18 per share. | 01 Jul 2024 | 25,000 | 25,928 | - | 41.2 | 1,029,535 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Jul 2024 | 25,000 | 50,928 | - | 3.5 | 87,500 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,290 | 25,928 | - | - | Common Stock | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 40.61 per share. | 03 Jun 2024 | 50,000 | 15,638 | - | 40.6 | 2,030,520 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 03 Jun 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 50,000 | 2,202,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 50,000 | 2,252,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 10 May 2024 | 50,000 | 15,638 | - | 42.1 | 2,105,125 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 10 May 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 42.33 per share. | 01 Apr 2024 | 50,000 | 15,638 | - | 42.3 | 2,116,640 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Apr 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 50,000 | 2,302,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 50,000 | 2,352,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 41.01 per share. | 04 Mar 2024 | 50,000 | 15,638 | - | 41.0 | 2,050,550 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 04 Mar 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 50,000 | 2,402,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 41.16 per share. | 29 Feb 2024 | 50,000 | 15,638 | - | 41.2 | 2,057,890 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 29 Feb 2024 | 50,000 | 65,638 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
Anthony N. Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 15,440 | 46,322 | - | - | Restricted Stock Units | |
|
Cerevel Therapeutics Holdi...
52 week high |
Coles Anthony N. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 15,440 | 18,144 | - | - | Common Stock | |
|
Cerevel Therapeutics Holdi...
52 week high |
Anthony N. Coles | Director | Sale of securities on an exchange or to another person at price $ 41.54 per share. | 06 Feb 2024 | 2,506 | 15,638 | - | 41.5 | 104,110 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
Anthony N. Coles | Director | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 02 Jan 2024 | 50,000 | 2,704 | - | 42.2 | 2,111,815 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Coles Anthony | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 50,000 | 2,452,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
Coles N. Anthony | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Jan 2024 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
|
Regeneron Pharmaceuticals,...
|
Anthony Coles N. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
|
Regeneron Pharmaceuticals,...
|
Coles N. Anthony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 1,393 (0%) | 0% | 0 | Common Stock | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 50,000 | 2,702,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 11 Jul 2023 | 50,000 | 2,704 | - | 30.0 | 1,501,340 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 11 Jul 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 32.60 per share. | 01 Jun 2023 | 50,000 | 2,704 | - | 32.6 | 1,630,070 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 50,000 | 2,752,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Jun 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 04 May 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 50,000 | 2,802,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 31.36 per share. | 04 May 2023 | 37,568 | 15,136 | - | 31.4 | 1,178,268 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 31.76 per share. | 04 May 2023 | 12,132 | 3,004 | - | 31.8 | 385,287 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 32.93 per share. | 04 May 2023 | 300 | 2,704 | - | 32.9 | 9,879 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 11 Apr 2023 | 50,000 | 52,704 | - | 3.5 | 175,000 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 50,000 | 2,852,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 11 Apr 2023 | 50,000 | 2,704 | - | 25.1 | 1,253,130 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Mar 2023 | 47,000 | 49,704 | - | 3.5 | 164,500 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 27.11 per share. | 02 Mar 2023 | 47,000 | 2,704 | - | 27.1 | 1,274,377 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 47,000 | 2,905,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Sale of securities on an exchange or to another person at price $ 27.19 per share. | 02 Mar 2023 | 3,000 | 2,704 | - | 27.2 | 81,570 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Mar 2023 | 3,000 | 5,704 | - | 3.5 | 10,500 | Common Stock |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2023 | 3,000 | 2,902,417 | - | - | Stock Option (Right to Buy) | |
|
Cerevel Therapeutics Holdi...
52 week high |
N. Anthony Coles | Director, CEO and Chairperson | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 243,042 | 243,042 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges